Evaluating Spatial Transcriptomics Platforms for IBD Clinics & Research labroots.com

Evaluating Spatial Transcriptomics Platforms for IBD Clinics & Research

2 min read
Why This Matters

Spatial transcriptomics helps map where genes are expressed in intestinal tissue, which can reveal cellular mechanisms of IBD and guide research. Knowing which platforms give more reliable data matters for multicenter studies and for building robust computational tools that could support future diagnostics or research.

Who Should Pay Attention

Researchers working with spatial transcriptomics or single-cell datasets, clinicians involved in IBD research or digital pathology, and patient communities interested in research advances in IBD.

What To Know

What To Know Researchers built a large cellular atlas of the gastrointestinal tract using single-cell data from over 3 million cells across samples from ulcerative colitis, Crohn's disease, and unaffected individuals.

They used this atlas to benchmark two spatial transcriptomics platforms (CosMx and Xenium) for their ability to detect gene expression patterns in tissue.

The study reported that CosMx had higher detection efficiency and greater stability across variable sample preparations compared with Xenium on the panels tested, though performance varied by tissue type and other parameters. The authors plan to expand the dataset and apply computational tools to improve analysis and to train digital pathology/AI models.

spatial transcriptomics shows where genes are active in tissue and can reveal cellular interactions that drive IBD; reliable platforms are important for multicenter research and developing computational tools that could eventually aid research and clinical workflows.

The article summarizes published work (Nature Communications) and commentary from study authors at Northwestern; it focuses on platform benchmarking rather than reporting a new treatment or clinical guideline.

Keep In Mind

This is an early-stage, research-focused study benchmarking laboratory platforms and describing a large cellular atlas. It does not change clinical care now. Platform performance can vary by tissue preparation and panel choice, and the researchers intend to expand and refine the dataset and computational methods.

This Cure8 note is AI-assisted and based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Read Original Article Originally published May 25, 2026, 8:30 AM
Advertisement Space

Related Articles